In vitro coagulation effects of ophthalmic doses of bevacizumab.
Document Type
Article, Non peer-reviewed
Publication Date
6-8-2012
Abstract
PURPOSE: In vitro coagulation effects of bevacizumab, a drug with potential risks for severe hemorrhagic and arterial thromboembolic events (ATEs), are unknown. The aim of this study was to evaluate the effects of bevacizumab, including the common ophthalmic dose of 1.25 mg, on the coagulation cascade. METHODS: Bevacizumab doses of 0.25, 0.5, 1.0, 1.25, 2.0, 2.5, and 4.0 mg were incubated at 37 degrees C in the presence of pooled normal plasma (PNP) to determine its biological activity via activated partial thromboplastin time (aPTT) and prothrombin time (PT) at 30 min, 1 h, and 2 h. The control consisted of 40% normal saline and 60% PNP. All evaluations were conducted in triplet. Coagulation at each time point was compared with the control group by analysis of variance with Tukey's post hoc test. A P value of
Recommended Citation
Li, Emily; Greenberg, Paul B.; Tseng, Victoria; Woodmansee, Suzanne B.; Caffrey, Aisling R.; Wu, Wen-Chih; Friedmann, Peter D.; and Laplante, Kerry L., "In vitro coagulation effects of ophthalmic doses of bevacizumab." (2012). All Scholarly Works. 8374.
https://scholarlycommons.libraryinfo.bhs.org/all_works/8374
PMID
22304563